LAWSUITS NEWS & LEGAL INFORMATION< Back to Press Releases
Elidel approved only for short-term, intermittent use.
Further concerns about Elidel
Washington, DC: A case in Pennsylvania against Novartis, involves a toddler who developed cancer due to a failure-to-warn about the risks associated with the topical drug Elidel. In an important decision sure to have an impact on many other cases in the US, on October 16, 2006, a US District Court in Eastern Pennsylvania refused to grant the drug maker's preemption motion in, Perry v Novartis Pharma Corp, -- F Supp 2d ---, 2006 WL 2979388.
Elidel was approved by the FDA on December 13, 2001, to treat atopic dermatitis, commonly known as eczema, in a cream applied directly to the skin, for persons over the age of two.
Elidel belongs to a class of immunosuppressant drugs known as calcineurin inhibitors. At the time of its approval, there were already concerns about an association between Elidel and cancer because other calcineurin inhibitors that were used to treat organ transplant patients were known to increase the risk of cancer and lymphoma, and carried a Black Box warning to that affect.
At the time of its approval, Elidel had also been found to increase the risk of cancer in animals when administered at high doses.
Because of its concerns about cancer, the FDA placed restrictions on Elidel and approved it only for short-term and intermittent use, and as a second-line of treatment to be used only when traditional therapies such as corticosteroids were found to be ineffective.
Further information about Elidel
Online Legal Marketing offers a comprehensive website with up-to-date legal news, class action lawsuits, personal injury cases, settlement details, product recalls, and more. Consumers receive free claim evaluations from lawyers who advertise on the website.
Online Legal Marketing